Selective Targeting of Lysyl Oxidase-like 2 (LOXL2) Suppresses Hepatic Fibrosis Progression and Accelerates Its Reversal

Overview

Journal Gut

Specialty Gastroenterology

Date 2017 Jan 12

PMID 28073888

Citations 129

Authors

Naoki Ikenaga

Zhen-Wei Peng

Kahini A Vaid

Susan B Liu

Shuhei Yoshida

Deanna Y Sverdlov

Amanda Mikels-Vigdal

Victoria Smith

Detlef Schuppan

Yury V Popov

Affiliations

Soon will be listed here.

Abstract

Background/aims: We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice.

Methods: Anti-LOXL2 antibody, control antilysyl oxidase antibody or placebo was administered during thioacetamide (TAA)-induced fibrosis progression or during recovery. Therapeutic efficacy in biliary fibrosis was tested in BALB/c. and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice. Collagen crosslinking, fibrosis progression and reversal were assessed histologically and biochemically. HPC differentiation was studied in primary EpCAM(+) liver cells in vitro.

Results: LOXL2 was virtually absent from healthy but strongly induced in fibrotic liver, with predominant localisation within fibrotic septa. Delayed anti-LOXL2 treatment of active TAA fibrosis significantly reduced collagen crosslinking and histological signs of bridging fibrosis, with a 53% reduction in morphometric collagen deposition. In established TAA fibrosis, LOXL2 inhibition promoted fibrosis reversal, with enhanced splitting and thinning of fibrotic septa, and a 45% decrease in collagen area at 4 weeks of recovery. In the Mdr2-/- and DDC-induced models of biliary fibrosis, anti-LOXL2 antibody similarly achieved significant antifibrotic efficacy and suppressed the ductular reaction, while hepatocyte replication increased. Blocking LOXL2 had a profound direct effect on primary EpCAM(+) HPC behaviour in vitro, promoting their differentiation towards hepatocytes, while inhibiting ductal cell lineage commitment.

Conclusions: LOXL2 mediates collagen crosslinking and fibrotic matrix stabilisation during liver fibrosis, and independently promotes fibrogenic HPC differentiation. By blocking these two convergent profibrotic pathways, therapeutic LOXL2 inhibition attenuates both parenchymal and biliary fibrosis and promotes fibrosis reversal.

Citing Articles

Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells.

Li W, Sparks R, Sun C, Yang Y, Pantano L, Kirchner R Nat Commun. 2025; 16(1):2109.

PMID: 40025044 PMC: 11873113. DOI: 10.1038/s41467-025-56900-z.

Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.

Geng W, Liao W, Cao X, Yang Y Biomedicines. 2025; 13(2).

PMID: 40002806 PMC: 11853636. DOI: 10.3390/biomedicines13020393.

Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.

Durazzo M, Ferro A, Navarro-Tableros V, Gaido A, Fornengo P, Altruda F Biomolecules. 2025; 15(1).

PMID: 39858515 PMC: 11763965. DOI: 10.3390/biom15010121.

Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine.

Cassani M, Fernandes S, Pagliari S, Cavalieri F, Caruso F, Forte G Adv Sci (Weinh). 2024; 12(2):e2409898.

PMID: 39629891 PMC: 11727388. DOI: 10.1002/advs.202409898.

Hic-5 antisense oligonucleotide inhibits advanced hepatic fibrosis and steatosis .

Noguchi M, Miyauchi A, Masaki Y, Sakaki M, Lei X, Kobayashi-Tanabe M JHEP Rep. 2024; 6(11):101195.

PMID: 39444410 PMC: 11497448. DOI: 10.1016/j.jhepr.2024.101195.

References

Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E . Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16):1483-93. DOI: 10.1056/NEJMoa1316366. View

Xie G, Karaca G, Swiderska-Syn M, Michelotti G, Kruger L, Chen Y . Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice. Hepatology. 2013; 58(5):1801-13. PMC: 3758784. DOI: 10.1002/hep.26511. View

Lucero H, Kagan H . Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci. 2006; 63(19-20):2304-16. PMC: 11136443. DOI: 10.1007/s00018-006-6149-9. View

Yoshida S, Ikenaga N, Liu S, Peng Z, Chung J, Sverdlov D . Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014; 147(6):1378-92. DOI: 10.1053/j.gastro.2014.08.038. View

Dorrell C, Erker L, Schug J, Kopp J, Canaday P, Fox A . Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev. 2011; 25(11):1193-203. PMC: 3110957. DOI: 10.1101/gad.2029411. View

Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez H, Oyasu M . Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010; 16(9):1009-17. DOI: 10.1038/nm.2208. View

Canesin G, Cuevas E, Santos V, Lopez-Menendez C, Moreno-Bueno G, Huang Y . Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. Oncogene. 2014; 34(8):951-64. DOI: 10.1038/onc.2014.23. View

Popov Y, Sverdlov D, Sharma A, Bhaskar K, Li S, Freitag T . Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology. 2011; 140(5):1642-52. PMC: 3374132. DOI: 10.1053/j.gastro.2011.01.040. View

Peng Z, Ikenaga N, Liu S, Sverdlov D, Vaid K, Dixit R . Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis. Hepatology. 2015; 63(1):217-32. PMC: 5312042. DOI: 10.1002/hep.28274. View

10.

Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar K, Niedobitek G . Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. 2008; 48(3):453-64. DOI: 10.1016/j.jhep.2007.11.021. View

11.

Herranz N, Dave N, Millanes-Romero A, Morey L, Diaz V, Lorenz-Fonfria V . Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell. 2012; 46(3):369-76. DOI: 10.1016/j.molcel.2012.03.002. View

12.

Huch M, Dorrell C, Boj S, van Es J, Li V, van de Wetering M . In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013; 494(7436):247-50. PMC: 3634804. DOI: 10.1038/nature11826. View

13.

Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y . Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015; 30(7):1183-9. DOI: 10.1111/jgh.12915. View

14.

Clouston A, Powell E, Walsh M, Richardson M, Demetris A, Jonsson J . Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. 2005; 41(4):809-18. DOI: 10.1002/hep.20650. View

15.

Friedman S . Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134(6):1655-69. PMC: 2888539. DOI: 10.1053/j.gastro.2008.03.003. View

16.

Roskams T, Desmet V . Ductular reaction and its diagnostic significance. Semin Diagn Pathol. 1998; 15(4):259-69. View

17.

Ikenaga N, Liu S, Sverdlov D, Yoshida S, Nasser I, Ke Q . A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol. 2014; 185(2):325-34. DOI: 10.1016/j.ajpath.2014.10.013. View

18.

Richardson M, Jonsson J, Powell E, Brunt E, Neuschwander-Tetri B, Bhathal P . Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007; 133(1):80-90. DOI: 10.1053/j.gastro.2007.05.012. View

19.

Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N . A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013; 57(2):230-6. DOI: 10.1093/cid/cit234. View

20.

Barker H, Cox T, Erler J . The rationale for targeting the LOX family in cancer. Nat Rev Cancer. 2012; 12(8):540-52. DOI: 10.1038/nrc3319. View